Drug
Daratumumab clinical trials
Also written Darzalex, JNJ-54767414 and HuMax-CD38.
- studies test it
- 219
- open now
- 55
- in phase 3
- 28
- first study started
- 2008
Keep track of what changes. Save the daratumumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Daratumumab
- 170
Brand
- Darzalex
- 78
Development codes
Combined with it in one product
- Dara
- 2
Biosimilars in development
- HLX15
- 2
Studies by the year they started
219 studies that test it; most in 2021 (27)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 8 |
| 2016 | 9 |
| 2017 | 26 |
| 2018 | 25 |
| 2019 | 23 |
| 2020 | 19 |
| 2021 | 27 |
| 2022 | 18 |
| 2023 | 19 |
| 2024 | 13 |
| 2025 | 15 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 61
- Phase 2
- 147
- Phase 3
- 28
- Phase 4
- 6
- No phase
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 60 · Other 159
Janssen Research & Development, LLC (27) · Institute of Hematology & Blood Diseases Hospital, China (11) · Mayo Clinic (10) · M.D. Anderson Cancer Center (8) · Hellenic Society of Hematology (6) · City of Hope Medical Center (5) · Memorial Sloan Kettering Cancer Center (5) · Stichting European Myeloma Network (5)
Often tested with
Tested in the same studies.
Dexamethasone (72) · Lenalidomide (34) · Bortezomib (26) · Pomalidomide (21) · Carfilzomib (20) · Ixazomib (10) · Cyclophosphamide (9) · Hyaluronidase (human recombinant) (5)
Studies
Open first, then newest update. How each study uses daratumumab is read from its arms, and is right about nine times in ten.
Testing it · 219
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)RecruitingPhase 1/2AbbVieNCT06953960Written as Daratumumab
- Daratumumab in Primary Antiphospholipid SyndromeRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT05671757Written as Daratumumab
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1Genentech, Inc.NCT04910568Written as Daratumumab
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingPhase 1/2AbbVieNCT06892522Written as Daratumumab
- Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseRecruitingPhase 2National Cancer Institute (NCI)NCT05907759Written as Daratumumab SC
- Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA TrialRecruitingPhase 2Mayo ClinicNCT05898646Written as Daratumumab
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingPhase 1/2BeOne MedicinesNCT04973605Written as Daratumumab
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingPhase 3PfizerNCT05623020Written as Daratumumab
- A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple MyelomaRecruitingPhase 1Janssen Research & Development, LLCNCT06768489Written as Daratumumab
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07830485Written as Daratumumab
- A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingPhase 2Hackensack Meridian HealthNCT04661137Written as Daratumumab
- The Effect of Daratumumab in Patients With Monoclonal Gammopathy of Renal Significance (MGRS) in FinlandRecruitingPhase 2Helsinki University Central HospitalNCT06889948Written as Daratumumab
- Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALLRecruitingPhase 2Eastern Cooperative Oncology GroupNCT05289687Written as Daratumumab / Hyaluronidase Injection
- Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & LymphomaRecruitingPhase 1New York Medical CollegeNCT04972942Written as Daratumumab
- Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.RecruitingPhase 2Fondazione Italiana Linfomi - ETSNCT04915248Written as Daratumumab
- Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune ThrombocytopeniaRecruitingPhase 4Institute of Hematology & Blood Diseases Hospital, ChinaNCT07788456Written as Daratumumab
- A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingPhase 3PfizerNCT05020236Written as Daratumumab
- Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT03937635Written as Daratumumab
- Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingPhase 1Andrew Hantel, MDNCT07341867Written as Daratumumab
- Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic LymphomaRecruitingPhase 1M.D. Anderson Cancer CenterNCT07513129Written as Daratumumab
See all 219 studies that test daratumumab →
Given in every arm · 70 — daratumumab is usual care beside what is tested
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07887672Written as Daratumumab
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)RecruitingPhase 3Regeneron PharmaceuticalsNCT07222761Written as Daratumumab
- A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantRecruitingPhase 2/3AbbVieNCT07095452Written as Daratumumab
- A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1/2AstraZenecaNCT07681596Written as Daratumumab
- A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not PlannedRecruitingPhase 3Janssen Research & Development, LLCNCT07665450Written as Daratumumab
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM PatientsRecruitingPhase 3Intergroupe Francophone du MyelomeNCT06918002Written as Daratumumab SC (Darzalex)
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT05552222Written as Daratumumab
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Daratumumab
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)RecruitingPhase 3Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06615479Written as Daratumumab
- Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early RelapseRecruitingPhase 2Larysa SanchezNCT06827860Written as Daratumumab
- A Open-Label Phase in Participants With Multiple MyelomaNot yet recruitingPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT07764861Written as Daratumumab
- Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTRecruitingPhase 3AstraZenecaNCT07764978Written as Daratumumab
- FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple MyelomaNot yet recruitingPhase 1Medical College of WisconsinNCT07221032Written as Daratumumab 16 mg/kg
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as Daratumumab
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingPhase 3University of LeedsNCT07649525Written as Daratumumab
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Daratumumab
- Optimize First-line Treatment for AL Amyloidosis With t (11; 14)RecruitingNot applicableJin Lu, MDNCT06192979Written as Daratumumab
- GMMG-HD11/DSMM XXI/64007957MMY3010Not yet recruitingPhase 3University of Heidelberg Medical CenterNCT07671287Written as Daratumumab
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingPhase 1/2CellCentric Ltd.NCT04068597Written as Daratumumab
- Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple MyelomaRecruitingPhase 2SCRI Development Innovations, LLCNCT06974786Written as Daratumumab
Showing 20 of 70.
As the comparator · 26 — what is tested is compared with daratumumab
- A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)RecruitingPhase 3Regeneron PharmaceuticalsNCT07393282Written as Daratumumab
- Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple MyelomaRecruitingPhase 3Canadian Cancer Trials GroupNCT06182774Written as Daratumumab
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingPhase 3Hoffmann-La RocheNCT07555938Written as Daratumumab
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)RecruitingPhase 3AstraZenecaNCT07391657Written as Daratumumab
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07623798Written as Daratumumab Injection (Subcutaneous Injection)
- Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) AmyloidosisNot yet recruitingPhase 3AbbVieNCT07793422Written as Daratumumab
- A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)RecruitingPhase 3BiocadNCT07742215Written as Daratumumab + pomalidomide + dexamethasone
- A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseNot yet recruitingPhase 3Polish Myeloma ConsortiumNCT07740486Written as Daratumumab (Subcutaneously)
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingPhase 3AbbVieNCT07728188Written as Daratumumab
- A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)RecruitingPhase 3GlaxoSmithKlineNCT06679101Written as Daratumumab
- A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 3Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT07452198Written as Daratumumab
- A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male SubjectsNot yet recruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT07400744Written as Darzalex
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)RecruitingPhase 3Nanjing IASO Biotechnology Co., Ltd.NCT06464991Written as Daratumumab
- Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)Not yet recruitingPhase 2Nantes University HospitalNCT06931704Written as Daratumumab
- A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Shanghai Henlius BiotechNCT06895512Written as Darzalex
- A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple MyelomaRecruitingPhase 3BiocadNCT06296121Written as Darzalex
- Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisActive, not recruitingPhase 1/2Columbia UniversityNCT05451771Written as Daratumumab Injection
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaActive, not recruitingPhase 3Kite, A Gilead CompanyNCT06413498Written as Daratumumab
- A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)WithdrawnPhase 2/3Regeneron PharmaceuticalsNCT07428369Written as Daratumumab
- GEN3014 Trial in Relapsed or Refractory Hematologic MalignanciesTerminatedPhase 1/2GenmabNCT04824794Written as Daratumumab
Showing 20 of 26.
Codes
What other systems call daratumumab · ClinicalTrials.gg INT005784
- MeSH (NLM) C556306daratumumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4Z63YK6E0EDARATUMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1721947Confirmed FDA, Wikidata
- Wikidata Q5222113daratumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74007DaratumumabOne source FDA
- DrugBank DB09331One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C556306 | daratumumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4Z63YK6E0E | DARATUMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1721947 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5222113 | daratumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74007 | Daratumumab | One source FDA |
| DrugBank | DB09331 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.